XT Amplify Adoption
Q: How will XT Amplify impact revenue and adoption?
A: The XT Amplify platform is expected to drive customer adoption through new innovations beyond just a console upgrade. While connected devices remain mostly capital, Amplify introduces services that could impact revenue recognition over time. All components are bookable now, and there's significant customer engagement and demand.

Customer Capital Spending
Q: Are customers increasing spending or still cautious?
A: Customer health varies; some are improving, but many remain cautious with capital equipment expenditures, particularly in inpatient settings. The company notes sensitivity around capital deployments, and customers are prudent about timing.

Guidance and Revenue Outlook
Q: Does recent performance affect full-year guidance?
A: Despite a strong first quarter, the company is maintaining its guidance and not changing its outlook. They acknowledge headwinds with some customers but continue to track to the provided guidance. They remain comfortable with their product outlook, which is slightly higher this year, contemplating the launch of Amplify.

RDS Divestiture
Q: Does divesting RDS mean exiting international markets?
A: The RDS divestiture does not signal an exit from international markets. It's part of an ongoing plan to ensure investments generate the right returns for shareholders.

Cost Savings Initiatives
Q: Are cost-saving measures fully reflected in guidance?
A: The majority of cost savings were realized in the first quarter, with a smaller portion anticipated throughout the year. The company continues to evaluate its cost structure to improve financial performance.

Enliven Business Update
Q: What's the outlook for Enliven?
A: The Enliven business has seen a good start to the year with new wins, primarily in new rooftops. These wins will contribute to annual recurring revenue moving forward, and the company is cautiously optimistic about steady long-term growth.

Impact of Change Healthcare Disruption
Q: Any impact from Change Healthcare disruption?
A: The company hasn't seen any impact on its business from the Change Healthcare disruption but is monitoring the situation closely ,.

340B Program Trends
Q: Update on 340B program volumes?
A: The 340B third-party administration business remains in line with last year, generating about $30 million to $35 million annually. The company expects it to be flat in 2024 but sees it as a valuable part of their strategy, combining it with specialty pharmacy services ,.

Specialty Pharmacy Consulting
Q: How does specialty pharmacy consulting inform product development?
A: Specialty pharmacy consulting engages at a high level with clients, allowing the company to discuss improving revenues and cost impacts in pharmacy operations. This informs product development, particularly in addressing outpatient clinic needs.

XT Amplify Offerings
Q: What are the XT Amplify solutions available?
A: XT Amplify includes solutions like XT Extend (console upgrade), Care Plus (workflow redesign), and Server Scale (scalable server capacity as a service). All are available for order today, with strong customer interest.

Services Revenue Timing
Q: What contributed to services revenue pull forward?
A: The timing impact was primarily driven by increased demand in advanced services and technical services. The company expects this to even out over the course of the year, maintaining their guidance outlook.

IVX Robots Regulatory Review
Q: Update on regulatory review of IVX robots?
A: At the end of last year, there was final resolution on some regulations. The company now has clearer determination on classifying robot locations and applicable regulations as they deploy.

Outcomes-Based Solutions
Q: Plans for outcomes-based solution approaches?
A: The company recognizes the importance of medication management in patient outcomes and finances. They're focusing on connecting pharmacy activities to patient episodes, particularly in retail cloud-based solutions.